Soda Yasushi

ソダヤスシ | Soda Yasushi

Affiliation and department：
Job title： Project Associate Professor

Research field (1)： Tumor biology

Research theme for competitive and other funds (9)：

2021 - 2024 Development of evolutional gene modified T cell transfusion therapy using novel and self-developed measles viral vector
2020 - 2023 メチオニン分解酵素遺伝子搭載によるバイスタンダー効果誘導腫瘍溶解性ウィルスの開発
2019 - 2022 グリオブラストーマの抗血管療法抵抗性の克服:残存腫瘍の浸潤性抑制法の開発
2018 - 2020 Development of novel therapeutic strategies for glioblastoma by mitochondria activation
2005 - 2007 Establishment of gene transfer to hematopoietic cells from patients with congenital neutropenia

Show all

Papers (65)：

Akira Sakamoto, Hiroyuki Inoue, Shohei Miyamoto, Shun Ito, Yasushi Soda, Kenzaburo Tani. Coxsackievirus A11 is an immunostimulatory oncolytic virus that induces complete tumor regression in a human non-small cell lung cancer. Scientific reports. 2023. 13. 1. 5924-5924
Miyako Sagara, Shohei Miyamoto, Shun Itoh, Yasushi Soda, Kenzaburo Tani. Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3. Anticancer research. 2021. 41. 1. 81-89
Lisa Hirose, Takafumi Hiramoto, Yamin Tian, Hiroshi Kohara, Seiichiro Kobayashi, Etsuko Nagai, Tamami Denda, Yukihisa Tanaka, Yasunori Ota, Liao Jiyuan, et al. A pilot study to establish human T-cell leukemia virus type 1 (HTLV-1) carrier model using common marmoset (Callithrix jacchus). Journal of medical primatology. 2020. 49. 2. 86-94
Takafumi Hiramoto, Maino Tahara, Jiyuan Liao, Yasushi Soda, Yoshie Miura, Ryo Kurita, Hiroshi Hamana, Kota Inoue, Hiroshi Kohara, Shohei Miyamoto, et al. Non-transmissible MV Vector with Segmented RNA Genome Establishes Different Types of iPSCs from Hematopoietic Cells. Molecular therapy : the journal of the American Society of Gene Therapy. 2020. 28. 1. 129-141
Miyamoto Shohei, Jia Yang, Soda Yasushi, Sagara Miyako, Liao Jiyuan, Hirose Lisa, Hijikata Yasuki, Hara Kenichiro, Iwanaga Atsufumi, Tani Kenzaburo. Dual microRNA Engineered Oncolytic Coxsackievirus Virotherapy for Clinical Trial. MOLECULAR THERAPY. 2019. 27. 4. 122-122

ｍore...

MISC (83)：

相良京, 宮本将平, 伊藤駿, 坂本旭, 曽田泰, 秋山徹, 谷憲三朗. 第二世代遺伝子改変コクサッキーウイルスB群3型の非臨床試験(Preclinical studies of a second-generation recombinant coxsackievirus B3). 日本癌学会総会記事. 2022. 81回. P-1377
児玉健, 曽田泰, 大野春香, 廖紀元, 宮本将平, 四柳宏, 谷憲三朗. 5-アミノレブリン酸とSFCの併用は鎌状赤血球症モデルマウスの出血ストレスおよびLPS誘発致死を防ぐ(5-ALA combined with SFC prevents blood-withdrawal stress and LPS-induced lethality in SCD mice). 日本血液学会学術集会. 2021. 83回. BPA-4
坂本旭, 井上博之, 宮本将平, 相良京, 伊藤駿, 曽田泰, 秋山徹, 谷憲三朗. Echovirus 4を用いた食道扁平上皮癌に対する新規腫瘍溶解性ウイルス療法の開発. 日本癌学会総会記事. 2021. 80回. [P21-5]
伊藤駿, 宮本将平, 相良京, 坂本旭, 曽田泰, 秋山徹, 谷憲三朗. 臨床試験に向けたmiRNA制御性腫瘍溶解性ウイルス療法の開発及び製造. 日本癌学会総会記事. 2021. 80回. [P21-4]
児玉健, 曽田泰, 大野春香, 廖紀元, 宮本将平, 四柳宏, 谷憲三朗. 5-アミノレブリン酸とSFCの併用は鎌状赤血球症モデルマウスの出血ストレスおよびLPS誘発致死を防ぐ(5-ALA combined with SFC prevents blood-withdrawal stress and LPS-induced lethality in SCD mice). 日本血液学会学術集会. 2021. 83回. BPA-4

ｍore...

Patents (2)：

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page